

SOTROVIMAB

BRAND NAME	XEVUDY
DRUG CLASS	Immunoglobulin (IgG1) monoclonal antibody (human), antiviral (SARS-CoV-2)
AVAILABILITY	Vial contains 500 mg/8 mL of sotrovimab. Also contains histidine, histidine hydrochloride, sucrose, methionine, polysorbate-80. ¹ The solution is clear and colourless to yellow or brown. ¹ The vial has an overfill of 0.6 mL to allow a deliverable volume of 8 mL. ²
WARNINGS	<div style="border: 2px solid red; padding: 5px;"><p>The occupational hazard of intermittent low dose exposure to sotrovimab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure.</p><p>Hypersensitivity reactions including anaphylaxis may occur. Resuscitation facilities must be readily available. Monitoring is required for one hour after the infusion.¹</p></div>
PREPARATION	Dilute before use. ¹ Allow 15 minutes for the vial (leave in the box) to reach room temperature. Gently swirl the vial several times. Do not shake. ¹ Remove and discard 8 mL from a 50 mL or 100 mL bag of sodium chloride 0.9% or glucose 5%. ¹ If local protocols allow, this step may be omitted. Add 8 mL of sotrovimab to the bag, gently rock the bag 3 to 5 times. Do not invert or shake the bag. Do not allow air bubbles to form. ¹
STABILITY	Vial: store at 2 to 8 °C. Protect from light. Do not freeze. ¹ Infusion solution: stable for 6 hours below 25 °C or 24 hours at 2 to 8 °C. ¹
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Contraindicated ¹
IV infusion	See PREPARATION. Infuse over 30 minutes. Use a 0.2 micrometre inline filter. ¹
COMPATIBILITY	
Fluids	Glucose 5% ¹ , sodium chloride 0.9% ¹
Y-site	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	Monitor for possible anaphylactic and infusion reactions during the infusion and for one hour after the infusion. ¹ Infusion reactions include fever, chills, dizziness, dyspnoea, pruritis and rash. ² For mild to moderate infusion reactions, slow or stop the infusion and treat accordingly. ¹ Anaphylactic reactions are rare but are a medical emergency. Stop the infusion and commence treatment immediately. ^{1,2}

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 26/08/2021.
2. Xevudy. Australian public assessment report. August 2021. Available from www.tga.gov.au. Accessed 26/08/2021.